相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A 52-week randomized trial
Guntram Schernthaner et al.
DIABETES CARE (2013)
A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes
E. Ferrannini et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
J-F Yale et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
K. Stenlof et al.
DIABETES OBESITY & METABOLISM (2013)
Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-treated Subjects With Type 2 Diabetes Mellitus
David Polidori et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter Inhibitor, as Add-On to Meiformin in Subjects With Type 2 Diabetes
Julio Rosenstock et al.
DIABETES CARE (2012)
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Julio Rosenstock et al.
DIABETES CARE (2012)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin
D. Devineni et al.
DIABETES OBESITY & METABOLISM (2012)
Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study
Patrick M. O'Neil et al.
OBESITY (2012)
Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
Wendy L. Bennett et al.
ANNALS OF INTERNAL MEDICINE (2011)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck et al.
DIABETES CARE (2011)
Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects
S. Sha et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
K. Strojek et al.
DIABETES OBESITY & METABOLISM (2011)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes
MN Cook et al.
DIABETES CARE (2005)
Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes - A 1-year randomized controlled trial
DE Kelley et al.
DIABETES CARE (2002)